Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04090034 · ClinicalTrials.gov registry record
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
A clinical trial of Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT04090034: Recruiting study of Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Methodist Health System.
NCT04090034 is a study of Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 50 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04090034, a study of Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
Primary Outcome
(such as age at diagnosis, sex, history of smoking alcohol use and symptoms at the time of diagnosis)
Conditions Studied
Interventions
- PROCEDURE Peptide Receptor Radionuclide Therapy
Study Locations (2)
Texas
- Clinical Research Institute at Methodist Health System - Dallas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2026-06-28 |
What NCT04090034 shows while recruiting
NCT04090034 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which Peptide Receptor Radionuclide Therapy is the first listed.
NCT04090034 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04090034 about?
NCT04090034 is a clinical study titled "Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors". The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
What is the current status of trial NCT04090034?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-03-28. Estimated completion is 2026-06-28.
What conditions does trial NCT04090034 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT04090034?
The interventions under investigation include: Peptide Receptor Radionuclide Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT04090034?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04090034 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04090034's enrollment target sits among peer trials
50 31st of 52 higher than 21 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI